文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

作为抗癌剂的微管相互作用天然产物。

Tubulin-interactive natural products as anticancer agents.

机构信息

Department of Chemistry, M/C 0212, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061-0212, USA.

出版信息

J Nat Prod. 2009 Mar 27;72(3):507-15. doi: 10.1021/np800568j.


DOI:10.1021/np800568j
PMID:19125622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2765517/
Abstract

This review provides an overview of the discovery, structures, and biological activities of anticancer natural products that act by inhibiting or promoting the assembly of tubulin to microtubules. The emphasis is on providing recent information on those compounds in clinical use or in advanced clinical trials. The vinca alkaloids, the combretastatins, NPI-2358, the halichondrin B analogue eribulin, dolastatin 10, noscapine, hemiasterlin, and rhizoxin are discussed as tubulin polymerization inhibitors, while the taxanes and the epothilones are the major classes of tubulin polymerization promoters presented, with brief treatments of discodermolide, eleutherobin, and laulimalide. The challenges and future directions of tubulin-interactive natural products-based drug discovery programs are also discussed briefly.

摘要

这篇综述概述了通过抑制或促进微管蛋白组装来发挥作用的抗癌天然产物的发现、结构和生物活性。重点是提供那些在临床使用或在临床试验中处于先进阶段的化合物的最新信息。长春碱类生物碱、考布他汀类、NPI-2358、海兔内酯类似物埃博霉素、多紫杉醇 10、石蒜碱、海兔内酯和瑞香毒素被讨论为微管蛋白聚合抑制剂,而紫杉醇类和埃坡霉素类则是主要的微管蛋白聚合促进剂类别,简要讨论了 discodermolide、eleutherobin 和 laulimalide。还简要讨论了基于微管蛋白相互作用的天然产物药物发现计划的挑战和未来方向。

相似文献

[1]
Tubulin-interactive natural products as anticancer agents.

J Nat Prod. 2009-3-27

[2]
Natural products as antimitotic agents.

Curr Top Med Chem. 2014

[3]
Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B.

Pharmacol Ther. 1992

[4]
Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.

Proc Natl Acad Sci U S A. 2021-3-2

[5]
Antimicrotubular drugs binding to vinca domain of tubulin.

Mol Cell Biochem. 2003-11

[6]
Mechanism of action of antitumor drugs that interact with microtubules and tubulin.

Curr Med Chem Anticancer Agents. 2002-1

[7]
Towards modern anticancer agents that interact with tubulin.

Eur J Pharm Sci. 2019-1-25

[8]
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data.

J Biol Chem. 1991-8-25

[9]
Anticancer therapy with novel tubulin-interacting drugs.

Drug Resist Updat. 2001-12

[10]
Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.

J Biol Chem. 1990-10-5

引用本文的文献

[1]
Discovery of nostatin A, an azole-containing proteusin with prominent cytostatic and pro-apoptotic activity.

Org Biomol Chem. 2025-1-2

[2]
Herbal Therapies for Cancer Treatment: A Review of Phytotherapeutic Efficacy.

Biologics. 2024-9-10

[3]
Natural Anticancer Peptides from Marine Animal Species: Evidence from In Vitro Cell Model Systems.

Cancers (Basel). 2023-12-20

[4]
Disturbing cytoskeleton by engineered nanomaterials for enhanced cancer therapeutics.

Bioact Mater. 2023-6-29

[5]
Crosstalk between Microtubule Stabilizing Agents and Prostate Cancer.

Cancers (Basel). 2023-6-23

[6]
Effect of the Marine Polyketide Plocabulin on Tumor Progression.

Mar Drugs. 2022-12-31

[7]
Integrated analysis reveals effects of bioactive ingredients from (Girard) Kuntze on hypoxia-inducible factor (HIF) activation.

Front Plant Sci. 2022-10-27

[8]
Synthesis and antitumor activity of litseaone B analogues as tubulin polymerisation inhibitors.

J Enzyme Inhib Med Chem. 2022-12

[9]
Drugs That Changed Society: Microtubule-Targeting Agents Belonging to Taxanoids, Macrolides and Non-Ribosomal Peptides.

Molecules. 2022-9-1

[10]
Cytotoxicity of phenylpironetin analogs and the metabolic fate of pironetin and phenylpironetin.

Bioorg Chem. 2022-8

本文引用的文献

[1]
(+)-Discodermolide: Total Synthesis, Construction of Novel Analogues, and Biological Evaluation.

Tetrahedron. 2007-1-7

[2]
Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate.

Expert Opin Investig Drugs. 2008-11

[3]
Clinical status of anti-cancer agents derived from marine sources.

Anticancer Agents Med Chem. 2008-8

[4]
Natural products to drugs: natural product-derived compounds in clinical trials.

Nat Prod Rep. 2008-6

[5]
Protein nanoparticles as drug carriers in clinical medicine.

Adv Drug Deliv Rev. 2008-5-22

[6]
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy.

Ann Oncol. 2008-7

[7]
Epothilones and new analogues of the microtubule modulators in taxane-resistant disease.

Expert Opin Investig Drugs. 2008-4

[8]
Antitumor activity of noscapine in human non-small cell lung cancer xenograft model.

Cancer Chemother Pharmacol. 2008-12

[9]
The structure activity relationship of discodermolide analogues.

Mini Rev Med Chem. 2008-3

[10]
New taxanes in development.

Expert Opin Investig Drugs. 2008-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索